| 名稱 | Aprepitant |
| 描述 | Aprepitant is a Substance P/Neurokinin-1 Receptor Antagonist. The mechanism of action of aprepitant is as a Neurokinin 1 Antagonist, and Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 2C9 Inducer, and Cytochrome P450 3A4 Inducer. |
| 細胞實驗 | Aprepitant is dissolved in DMSO. The inhibitory effect of aprepitant on metabolic activity of Nalm-6 cells is assessed by uptake of thiazolyl blue tetrazolium bromide (MTT) by viable cells. Cells are plated onto 96-well plates at a density of 5000 cells/well. After treatment with aprepitant at 5, 10, 15, 20 and 30 μM for 24, 36 and 48 h, the cells are further incubated with 100 μL of MTT (0.5 mg/mL) at 37°C for 3 h. Untreated cells are defined as the control group. Following solubilization of precipitated formazan with 100 μL of DMSO, the optical densitometry is measured with an ELISA reader at a wavelength of 578 nm. |
| 體外活性 | 在疼痛沖動從外周受體到CNS 的傳感中,Aprepitant起關鍵作用,并參與對壓力的各種行為及神經化學和心血管的反應.Aprepitant可穿透血腦屏障并與大腦中NK-1受體結合.Aprepitant可抑制化療引起的細胞毒性,如順鉑（阻斷P物質）誘發(fā)的急性和延遲性嘔吐.Aprepitant（3 mg/kg,i.v.或p.o.）可抑制順鉑（10 mg/kg,i.v.）引起的嘔吐.Aprepitant（0.1 mg/kg,i.v.）與地塞米松（20 mg/kg,i.v.）或5–HT3 受體拮抗劑恩丹西酮（0.1 mg/kg,i.v.）聯(lián)用可加強止吐效果.在雪貂急性遲緩性嘔吐模型中,順鉑（5 mg/kg,i.p.）給藥后惡心并嘔吐的回應記錄為72 h.Aprepitant（4-16 mg/kg,p.o.）預處理可劑量依賴性地抑制順鉑引起的嘔吐.Aprepitant（2-4 mg/kg/day,p.o.）完全抑制了所有給藥雪貂的惡心和嘔吐癥狀.通過注射順鉑24 h后可形成嘔吐急性期,開始每天給藥,順鉑注射后 24 和48 h,Aprepitant（4 mg/kg,p.o.） 抑制了75%雪貂的惡心和嘔吐癥狀. |
| 體內活性 | Aprepitant對人NK1受體的選擇性是人NK3受體的3000倍,比人NK2受體多出50,000倍。在使用人類和動物組織(IC50> 3 μM)進行的單胺攝取位點(NE, 5–HT, DA)計數(shù)篩選中,以及在人類單胺氧化酶A和B試驗以及人類血清素5–HT1A, 5–HT2A, 5–HT2c, 5–HT3, 5–HT5, 5–HT6,和5–HT7 受體(IC50>3 μM)中,Aprepitant均是無活性的。Aprepitant與CNS和外周的NK-1受體結合而拮抗P物質。CHO或 COS 細胞中hNK1受體上50%的P物質會被Aprepitant（0.1 nM）取代。在放射性配體結合試驗中,在放射性配體結合篩選的PANLABS 板中,采用原生動物組織,Aprepitant抑制大鼠頜下腺中[3H]P物質與天然NK1受體結合；經檢查PANLABS篩選,Aprepitant與其他任何原生動物G蛋白耦合的受體或離子通道均無明顯的相互作用。 |
| 存儲條件 | Keep away from direct sunlight,
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | 10% DMSO+90% Saline : < 10 mg/mL (18.71 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
Ethanol : 12 mg/mL (22.45 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (18.71 mM), Solution.
DMSO : 104 mg/mL (194.6 mM), Sonication is recommended.
|
| 關鍵字 | Tachykinin receptor | NK1 | NK receptor | Neurokininreceptor | Neurokinin Receptor | MK869 | MK0869 | MK 869 | MK 0869 | L754030 | L 754030 | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV Protease | HIV | Bacterial | Aprepitant | Antibiotic |
| 相關產品 | Levulinic acid | Emtricitabine | Neomycin sulfate | Dextran sulfate sodium salt (MW 5000) | Terbinafine hydrochloride | Chitosan hydrochloride (80%-90% deacetylated) | Lamivudine | Dimethyl sulfoxide | Hyaluronic acid sodium (MW 20 kDa) | Sodium diacetate | Sulfamethoxazole sodium | D(+)-Raffinose pentahydrate |
| 相關庫 | 抑制劑庫 | 抗癌上市藥物庫 | 經典已知活性庫 | 已知活性化合物庫 | EMA 上市藥物庫 | 臨床失敗化合物庫 | 高選擇性抑制劑庫 | FDA 上市藥物庫 | GPCR靶點分子庫 | 膜蛋白靶向化合物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 |